Prentice Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Prentice Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-81	Closed	-$8K	–	145
2022 Q2	$8K	Buy	+81	New	+$7.48K	0.01%	108
2021 Q4	–	Sell	-167	Closed	-$16K	–	233
2021 Q3	$16K	Sell	167 -51	-23%	-$4.82K	0.01%	224
2021 Q2	$21K	Sell	218 -8	-4%	-$767	0.01%	211
2021 Q1	$22K	Buy	+226	New	+$23.7K	0.01%	206

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Prentice Wealth Management's NBIX Position: Q3 2022 in Review

Prentice Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q3 2022, closing a stake of 81 shares — an estimated $8K sold.

Prentice Wealth Management first reported a position in NBIX in Q1 2021 and held it in 4 quarters. The position peaked at $22K in Q1 2021. 466 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

Prentice Wealth Management reported no remaining Neurocrine Biosciences position as of Q3 2022 after selling out during the quarter.
Prentice Wealth Management sold 81 Neurocrine Biosciences shares in Q3 2022, an estimated $8K.
Prentice Wealth Management first reported a position in Neurocrine Biosciences in Q1 2021 and held it in 4 quarters.
Prentice Wealth Management's Neurocrine Biosciences position peaked at $22K in Q1 2021.
466 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Prentice Wealth Management's 13F filing for Q3 2022, filed 19 Oct 2022.